Completed

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa

Lead sponsor

Ana Palanca

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

26,944

Study population

Cardiovascular disease, Chronic kidney disease, Heart failure, Obesity / overweight, Type 2 diabetes

Eligibility highlights

Primary endpoint

•Major acute cardiovascular events

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05535322

Org study IDGLP-1RA in T2D

Timeline

Milestones

Study start2014-01-01actual

Primary completion2019-12-31actual

Study completion2022-09-01actual

Study first posted2022-09-10actual

Last update posted2022-09-28actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Cardiovascular diseaseChronic kidney diseaseHeart failureObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age125 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

All identified adults with type 2 diabetes registered in the Population Information System (SIP) of the Valencian Community and corresponding to the Valencia Clínico-La Malvarrosa Health Department who were diagnosed before the end of the study period were included. Type 2 diabetes (T2D) diagnosis was defined according to the International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM, ICD-10-CM) codes. To exclude temporary treatment effects due to short-term use of the antidiabetic treatments, only individuals in the study groups with at least a 6-month prescription were included in the analyses.

Inclusion criteria

•Adults with type 2 diabetes

•Individuals with at least a 6-month prescription

Exclusion criteria

•Individuals below 18

•Individuals with less than a 6-month prescription

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Cardiovascular outcomes

Heart failure

Other clinical outcomes

Renal / kidney

Safety / tolerability / PK

Cardiovascular outcomes

2 endpoints

Primary/protocol endpoint

Major acute cardiovascular events

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Secondary/protocol endpoint

Stroke

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Heart failure

2 endpoints

Secondary/protocol endpoint

Major acute cardiovascular events without heart failure

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Secondary/protocol endpoint

Heart Failure

Time frame:Through study completion (from inclusion in the study until the event or the end of the study period, whichever came first)

descriptive

Renal / kidney

1 endpoint

Secondary/protocol endpoint

Renal progression

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Hypoglycemia

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Other clinical outcomes

2 endpoints

Secondary/protocol endpoint

all-cause death

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Secondary/protocol endpoint

Adherence

Time frame:From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.

descriptive

Other (unclassified)

4 endpoints

Secondary/protocol endpoint/low confidence

AMI

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Secondary/protocol endpoint/low confidence

atrial fibrillation

Time frame:From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.

descriptive

Secondary/protocol endpoint/low confidence

Persistence

Time frame:From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.

descriptive

Secondary/protocol endpoint/low confidence

Therapeutic inertia

Time frame:From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.